Switch theme
Sign up to access all valuation multiples
3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics.
2006
5.4K+
LTM Revenue $1.4B
LTM EBITDA $461M
$3.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
3SBio has a last 12-month revenue of $1.4B and a last 12-month EBITDA of $461M.
In the most recent fiscal year, 3SBio achieved revenue of $1.0B and an EBITDA of $325M.
3SBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 3SBio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $882M | $1.0B | XXX | XXX | XXX |
| Gross Profit | $678M | $729M | XXX | XXX | XXX |
| Gross Margin | 77% | 73% | XXX | XXX | XXX |
| EBITDA | $355M | $325M | XXX | XXX | XXX |
| EBITDA Margin | 40% | 32% | XXX | XXX | XXX |
| Net Profit | $212M | $246M | XXX | XXX | XXX |
| Net Margin | 24% | 24% | XXX | XXX | XXX |
| Net Debt | n/a | $293M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, 3SBio's stock price is HKD 13 (or $2).
3SBio has current market cap of HKD 30.6B (or $3.9B), and EV of HKD 28.2B (or $3.6B).
See 3SBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.6B | $3.9B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, 3SBio has market cap of $3.9B and EV of $3.6B.
3SBio's trades at 2.8x LTM EV/Revenue multiple, and 8.4x LTM EBITDA.
Analysts estimate 3SBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for 3SBio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.6B | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 11.2x | XXX | XXX | XXX |
| P/E | 19.7x | XXX | XXX | XXX |
| P/E/Growth | 0.5x | XXX | XXX | XXX |
| EV/FCF | 20.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign Up3SBio's NTM/LTM revenue growth is 11%
3SBio's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, 3SBio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate 3SBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for 3SBio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 43% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 38% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 54% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
3SBio acquired XXX companies to date.
Last acquisition by 3SBio was XXXXXXXX, XXXXX XXXXX XXXXXX . 3SBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was 3SBio founded? | 3SBio was founded in 2006. |
| Where is 3SBio headquartered? | 3SBio is headquartered in Hong Kong. |
| How many employees does 3SBio have? | As of today, 3SBio has 5.4K+ employees. |
| Who is the CEO of 3SBio? | 3SBio's CEO is Dr. Jing Lou, M.D.,PhD. |
| Is 3SBio publicy listed? | Yes, 3SBio is a public company listed on HKG. |
| What is the stock symbol of 3SBio? | 3SBio trades under 01530 ticker. |
| When did 3SBio go public? | 3SBio went public in 2015. |
| Who are competitors of 3SBio? | Similar companies to 3SBio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of 3SBio? | 3SBio's current market cap is $3.9B |
| What is the current revenue of 3SBio? | 3SBio's last 12-month revenue is $1.4B. |
| What is the current EBITDA of 3SBio? | 3SBio's last 12-month EBITDA is $461M. |
| What is the current EV/Revenue multiple of 3SBio? | Current revenue multiple of 3SBio is 2.8x. |
| What is the current EV/EBITDA multiple of 3SBio? | Current EBITDA multiple of 3SBio is 8.4x. |
| What is the current revenue growth of 3SBio? | 3SBio revenue growth between 2023 and 2024 was 14%. |
| Is 3SBio profitable? | Yes, 3SBio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
